Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CMMB 
Chemomab Therapeutics Ltd DRC (CMMB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: CMMB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $29.67
1 Year Target Price $29.67
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 17.54% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.74M USD | Price to earnings Ratio - | 1Y Target Price 29.67 |
Price to earnings Ratio - | 1Y Target Price 29.67 | ||
Volume (30-day avg) 2 | Beta 0.55 | 52 Weeks Range 2.70 - 9.84 | Updated Date 09/15/2025 |
52 Weeks Range 2.70 - 9.84 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -61.7% | Return on Equity (TTM) -120.16% |
Valuation
Trailing PE - | Forward PE 13 | Enterprise Value 6376417 | Price to Sales(TTM) - |
Enterprise Value 6376417 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.33 | Shares Outstanding 5191080 | Shares Floating 321955479 |
Shares Outstanding 5191080 | Shares Floating 321955479 | ||
Percent Insiders 16.73 | Percent Institutions 25.92 |
Upturn AI SWOT
Chemomab Therapeutics Ltd DRC
Company Overview
History and Background
Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics for fibrosis-related diseases with high unmet need. Founded with roots in academic research, the company has focused on leveraging its expertise in chemokines to develop disease-modifying therapies.
Core Business Areas
- Drug Development: Focused on the development of CM-101 (now Voccola), a CCL24-neutralizing antibody for fibrotic diseases. This includes preclinical research, clinical trials, and regulatory submissions.
Leadership and Structure
The company is led by a management team with expertise in drug development, clinical research, and business development. The organizational structure includes departments for research, clinical operations, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- Voccola (CM-101): Voccola (CM-101) is a monoclonal antibody targeting CCL24, a key driver of fibrosis. It is being investigated for rare fibrotic diseases like scleroderma and primary sclerosing cholangitis (PSC). Market share data is not readily available as the product is in clinical development and not yet commercialized. Competitors depend on the indication and include companies working on treatments for fibrotic diseases, such as Boehringer Ingelheim and Gilead Sciences in certain areas.
Market Dynamics
Industry Overview
The industry is characterized by a high unmet need for effective treatments for fibrotic diseases. It includes both large pharmaceutical companies and smaller biotechnology companies, with increasing focus on targeted therapies and personalized medicine.
Positioning
Chemomab is positioned as a company developing novel therapies for rare fibrotic diseases, focusing on CCL24 neutralization. Its competitive advantage lies in its specific therapeutic target and approach.
Total Addressable Market (TAM)
The TAM for fibrotic disease treatments is estimated to be in the billions of dollars. Chemomab is positioned to capture a share of this market by addressing unmet needs in specific rare fibrotic conditions. Estimated TAM for PSC alone is around $1-2 billion per year in the US and Europe.
Upturn SWOT Analysis
Strengths
- Novel therapeutic target (CCL24)
- Focus on rare fibrotic diseases with high unmet need
- Clinical-stage product candidate (Voccola)
- Experienced management team
Weaknesses
- Single clinical-stage product candidate
- Limited financial resources compared to larger pharmaceutical companies
- High risk associated with drug development
- Reliance on successful clinical trial outcomes
Opportunities
- Positive clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion of Voccola development into other fibrotic diseases
- Potential for orphan drug designation and market exclusivity
Threats
- Clinical trial failures
- Competition from other companies developing therapies for fibrotic diseases
- Regulatory hurdles
- Market access and pricing challenges
Competitors and Market Share
Key Competitors
- GILD
- BMY
- NVS
Competitive Landscape
Chemomab is a smaller player in the fibrotic disease market compared to large pharmaceutical companies. Its advantage is a focus on novel targets. The larger companies have bigger financial backing.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily driven by preclinical and clinical development progress of Voccola.
Future Projections: Future growth is dependent on the successful development and commercialization of Voccola and potential partnerships.
Recent Initiatives: Recent initiatives include ongoing clinical trials of Voccola in scleroderma and PSC, and exploration of potential indications.
Summary
Chemomab Therapeutics is a clinical-stage biotechnology company focused on rare fibrotic diseases. Its main product, Voccola, targets CCL24, a driver of fibrosis. Chemomab's success hinges on positive clinical trial outcomes and the ability to secure partnerships. The company faces risks associated with drug development and competition from larger pharmaceutical players. Its future growth depends on its capability to make it to the market with Voccola.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Chemomab Therapeutics Ltd DRC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-02-12 | Co-Founder, Chief Scientific Officer, CEO & Executive Director Dr. Adi Mor George Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.chemomab.com |
Full time employees - | Website https://www.chemomab.com | ||
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.